John Öhd, Modus Therapeutics' CEO, commented: ”The second quarter of 2023 was very productive for Modus and saw us make great progress in delivering on the broad clinical potential of sevuparin. We have continued to move forward with the planned clinical development of sevuparin for the treatment of sepsis, based on the positive initial clinical data that we have generated. In parallel, we have produced a compelling data set that highlights sevuparin’s potential in a new, and large opportunity, anemia related to chronic inflammation and kidney disease. This progress means we have significantly increased the potential value that we could generate from sevuparin while at the same time giving us greater control and optionality in how we develop the business. The next 12 months promise to be an exciting time for Modus Therapeutics, and I am looking forward to the future with great confidence.”

The second quarter in figures

• The loss after tax amounted to TSEK 4 695 (2 992).
• The loss per share amounted to SEK 0,29 (0,19).
• The cash flow from current operations was negative in the amount of TSEK 4 267 (3 228).

The first half-year in figures

• The loss after tax amounted to TSEK 10 735 (6 057).
• The loss per share amounted to SEK 0,67 (0,38).
• The cash flow from current operations was negative in the amount of TSEK 10 602 (10 773).

Important events during the second quarter

• Modus Therapeutics participated in LSX, London.
• The annual general meeting was held on May 11.
• Modus Therapeutics presented new data on sevuparin demonstrating its potential to treat anemia related to chronic inflammation and kidney disease at the annual European Hematology Association Congress.

Important events after the end of the period

No events to report.

CEO John Öhd will provide comments on the report in an interview with Jonathan Furelid today August 23 at 14:00 Link to Interview: https://www.youtube.com/watch?v=EqOVbiRP5iY